Chief Medical Officers, Clinical Research Executives, and Patient Advocacy Experts: attend DGE’s 2nd Diversity in Clinical Trials Summit, taking place May 10-11 in Philadelphia, PA. Join this unique in-person learning and networking experience aimed to remove obstacles in health equity and provide actionable strategies to increase diverse representation in clinical trials.
DGE is bringing together industry-leading experts from global clinical development to discuss the most critical challenges barriers, and methods on how to overcome barriers in order to reduce disparities and achieve health equity. The agenda focuses on increasing representation of underrepresented communities in clinical trials, improving collaborations with patient advocacy groups, rasping health literacy as a key component for clinical trial enrollment, improving clinical trial diversity through decentralized studies, increasing DE&I in clinical trial enrollment, and much more. Attendees will walk away with all new insights and practical strategies on how to effectively address and overcome the lack of diversity in clinical trials.
Why Diversity In Clinical Trials Is Essential
Improving the diversity of clinical trial participants is a crucial step towards enabling health equity and fighting healthcare discrepancies. The effectiveness of medicines and vaccines can vary based on gender, age, sex, ethnicity, and race. Therefore, clinical trials must have a proper representation of diverse patients to interpret the results and conclusions across all patient demographics.
The 2nd Diversity in Clinical Trials Summit concludes with networking sessions designed to provide participants with the optimized opportunity to create valuable new connections and foster existing relationships.
The summit’s agenda includes the following topics:
- Increasing representation of underrepresented communities in clinical trials
- Ensuring diverse participation in early drug development
- Setting goals for increasing diversity, equity, and inclusion (DE&I) in trial enrollment
- Standardizing diversity metrics in clinical trials
- Incorporating health literacy as a main component of clinical trial enrollment
- Improving alliances with patient advocacy groups
- Developing a diverse clinical research workforce
Improving diversity in clinical trials is both an ethical obligation and a scientific necessity. The lack of diversity offers a challenge in understanding how new therapies perform across different population subgroups, hampering progress in reducing differences and achieving equity. The 2nd Diversity in Clinical Trials Summit highlights the role of healthcare leaders in improving healthcare results for different populations.
To learn more, please visit https://ibn.fm/r0C5y.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]